Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Yahoo Finance anchor Julie Hyman tracks Thursday's top stocks and market movers in this Market Minute. C3.ai (AI) stock dips ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Superluminal partners with Eli Lilly to advance AI-driven small molecule therapeutics for cardiometabolic diseases.

Oracle (ORCL) stock is in focus on reports that the company will cut jobs in its cloud division — part of a broader push to ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

We recently published 10 Stocks On Jim Cramer’s Radar Including Big Tech Firms. Eli Lilly and Company (NYSE:LLY) is one of ...